This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Placido, S. Articles by Pignata, S. Search for Related Content PubMed PubMed Citation Articles by De Placido, S. Articles by Pignata, S. Social Bookmarking                            What's this?

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

From the Dipartimento di Endocrinologia e Oncologia Sperimentale e Clinica, Università Federico II di Napoli; Oncologia Medica, Ospedale Cardarelli; Oncologia Medica C, Oncologia Medica B, Ginecologia Oncologica, and Unità Operativa Sperimentazioni Cliniche, Istituto Nazionale Tumori di Napoli; Cattedra di Statistica Medica, Seconda Università di Napoli, Napoli; Istituto di Ginecologia ed Ostetricia, Policlinico Universitario Gemelli; Oncologia Medica, Azienda Ospedaliera S. Filippo Neri, Roma; Ginecologia II and I Clinica Ostetrica Ginecologica, Università di Bari; Oncologia Medica e Sperimentale, Istituto Nazionale Tumori di Bari, Bari; Clinica Malzoni, Avellino; Oncologia Medica, Ospedale Mariano Santo, Cosenza; Oncologia Medica, Azienda Ospedaliera S. Carlo, Potenza; Oncologia Medica, Ospedale Fatebenefratelli, Benevento; Oncologia Medica, Policlinico Giaccone, Palermo; and Ginecologia, Ospedale S Anna, Torino, Italy

Address reprint requests to Sandro Pignata, MD, PhD, Istituto Nazionale Tumori, via M Semmola, 80131–Napoli, Italy; e-mail: sandro.pignata{at}fondazionepascale.it

PURPOSE: Topotecan is an active second-line treatment for advanced ovarian cancer. Its efficacy as consolidation treatment after first-line standard chemotherapy is unknown.

PATIENTS AND METHODS: To investigate whether topotecan (1.5 mg/m² on days 1 through 5, four cycles, every 3 weeks) prolonged progression-free survival (PFS) for patients responding to standard carboplatin (area under the curve 5) and paclitaxel (175 mg/m² administered as a 3-hour infusion in six cycles; CP), a multicenter phase III study was performed with an 80% power to detect a 50% prolongation of median PFS. Patients were registered at diagnosis and randomized after the end of CP.

RESULTS: Two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years. Stage at diagnosis was advanced in three fourths of patients (stage III in 65% of patients; stage IV in 10%); after primary surgery, 46% had no residual disease and 20% were optimally debulked. After CP, 87% reached a clinical complete response, and 13% achieved a partial response. Neutropenia (grade 3/4 in 58% of the patients) and thrombocytopenia (grade 3 in 21%; grade 4 in 3%) were the most frequent toxicities attributed to topotecan. There was no statistically significant difference in PFS between the arms (P = .83; log-rank test): median PFS was 18.2 months in the topotecan arm and 28.4 in the control arm. Hazard ratio of progression for patients receiving topotecan was 1.18 (95% CI, 0.86 to 1.63) after adjustment for residual disease, interval debulking surgery, and response to CP.

CONCLUSION: The present analysis indicates that consolidation with topotecan does not improve PFS for patients with advanced ovarian cancer who respond to initial chemotherapy with carboplatin and paclitaxel.

The Unità Operativa Sperimentazioni Cliniche, Istituto Nazionale Tumori di Napoli, is supported by Associazione Italiana per la Ricerca sul Cancro and Clinical Trials Promoting Group.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Pecorelli, G. Favalli, A. Gadducci, D. Katsaros, P. B. Panici, A. Carpi, G. Scambia, M. Ballardini, O. Nanni, and P. Conte Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1 J. Clin. Oncol., October 1, 2009; 27(28): 4642 - 4648. [Abstract] [Full Text] [PDF]

				P. J. Hoskins Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy J. Clin. Oncol., March 20, 2009; 27(9): 1355 - 1358. [Full Text] [PDF]

				A. A. Garcia, H. Hirte, G. Fleming, D. Yang, D. D. Tsao-Wei, L. Roman, S. Groshen, S. Swenson, F. Markland, D. Gandara, et al. Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia J. Clin. Oncol., January 1, 2008; 26(1): 76 - 82. [Abstract] [Full Text] [PDF]

				V. Mobus, H. Wandt, N. Frickhofen, C. Bengala, K. Champion, R. Kimmig, H. Ostermann, A. Hinke, and J. A. Ledermann Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT J. Clin. Oncol., September 20, 2007; 25(27): 4187 - 4193. [Abstract] [Full Text] [PDF]

				G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann Current Management Strategies for Ovarian Cancer Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770. [Abstract] [Full Text] [PDF]

				J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. du Bois, U. Wagner, H. Bourgeois, W. Meier, S. Costa, J.-U. Blohmer, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst, August 2, 2006; 98(15): 1036 - 1045. [Abstract] [Full Text] [PDF]

				P. Sabbatini and D. R. Spriggs Consolidation for Ovarian Cancer in Remission J. Clin. Oncol., February 1, 2006; 24(4): 537 - 539. [Full Text] [PDF]

				R. H. Verheijen, L. F. Massuger, B. B. Benigno, A. A. Epenetos, A. Lopes, J. T. Soper, J. Markowska, R. Vyzula, T. Jobling, G. Stamp, et al. Phase III Trial of Intraperitoneal Therapy With Yttrium-90-Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission J. Clin. Oncol., February 1, 2006; 24(4): 571 - 578. [Abstract] [Full Text] [PDF]

				R. T. Penson and M. V. Seiden Topotecan: Weighing in When There Are Many Options Oncologist, October 1, 2005; 10(9): 698 - 700. [Abstract] [Full Text] [PDF]

				S. Pignata, F. Perrone, M. Di Maio, C. Gallo, and S. De Placido In Reply: J. Clin. Oncol., April 1, 2005; 23(10): 2436 - 2437. [Full Text] [PDF]

				K. Altundag, O. Altundag, P. Morandi, and M. Gunduz CA125 Nadir Values As a Prognostic Factor in Epithelial Ovarian Cancer J. Clin. Oncol., April 1, 2005; 23(10): 2435 - 2436. [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]